OCTREOTIDE ACETATE DRUG SUBSTANCE SPECIFICATION



Molecular weight: 1019.3 (free peptide)

Page 1 of 2

Sequence: H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol), supplied as acetate salt

Last update: 09 SEP 2019

Available registration documents (CTD format): DMF

| TEST | ACCEPTANCE CRITERION | ANALYTICAL PROCEDURE |
|---|---|----------------------|
| Appearance | White to off-white powder | Visual inspection |
| Identity, AAA (relative ratios) | Thr 0.7-1.1 Cys 1.0-2.2 Phe 1.8-2.2 Lys 0.9-1.3 Trp 0.4-1.1 Thr-ol 0.6-1.3 | USP |
| Identity, LC-UV | The retention time of the major peak of the sample solution corresponds to that of the standard solution and the major peak of the identification sample solution elutes as a single peak | USP |
| Octreotide content of the total mass of substance, LC-UV | To be noted | USP |
| Octreotide content (anhydrous and acetic acid-free substance) | 95.0 – 105.0% (w/w) | Calculation |
| Peptide related impurities, LC-UV Total impurities | ≤ 1.5 area% | USP |
| Water content, Karl Fisher method | ≤ 10.0% (w/w) | USP |
| Acetic acid content, LC-UV | 5.0-12.8% (w/w) | USP |
| TFA, LC-UV | ≤ 0.25% (w/w) | USP |

OCTREOTIDE ACETATE DRUG SUBSTANCE SPECIFICATION



Molecular weight: 1019.3 (free peptide)

Page 2 of 2

Sequence: H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol), supplied as acetate salt

Last update: 09 SEP 2019

Available registration documents (CTD format): DMF

| TEST | ACCEPTANCE CRITERION | ANALYTICAL PROCEDURE |
|-----------------------------|-------------------------------|----------------------|
| Residual solvents, GC | | |
| Acetonitrile | \leq 410 ppm (w/w) | In-house |
| DMSO | $\leq 5000 \text{ ppm (w/w)}$ | In-house |
| Microbial enumeration tests | | |
| TAMC | $\leq 100 \text{ CFU/g}$ | USP |
| TYMC | $\leq 100 \text{ CFU/g}$ | USP |
| Bacterial endotoxins | ≤ 466 EU/mg | USP |